Liquidia Co. (NASDAQ:LQDA) Shares Purchased by Eversept Partners LP

Eversept Partners LP raised its position in shares of Liquidia Co. (NASDAQ:LQDA - Free Report) by 314.1% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 571,305 shares of the company's stock after buying an additional 433,356 shares during the quarter. Eversept Partners LP owned about 0.67% of Liquidia worth $6,719,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the company. LM Advisors LLC purchased a new position in shares of Liquidia in the 4th quarter valued at approximately $25,948,000. Invesco Ltd. increased its stake in Liquidia by 2,675.0% during the 4th quarter. Invesco Ltd. now owns 700,171 shares of the company's stock valued at $8,234,000 after purchasing an additional 674,940 shares in the last quarter. Mirabella Financial Services LLP purchased a new position in shares of Liquidia in the fourth quarter worth $5,880,000. Renaissance Technologies LLC acquired a new stake in shares of Liquidia during the fourth quarter worth $2,681,000. Finally, JPMorgan Chase & Co. grew its holdings in shares of Liquidia by 855.3% during the third quarter. JPMorgan Chase & Co. now owns 235,393 shares of the company's stock valued at $2,354,000 after buying an additional 210,753 shares during the last quarter. 64.54% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Liquidia

In other news, insider Jason Adair sold 1,856 shares of the stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $13.57, for a total transaction of $25,185.92. Following the transaction, the insider now owns 184,304 shares in the company, valued at $2,501,005.28. This trade represents a 1.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Rajeev Saggar sold 2,450 shares of Liquidia stock in a transaction on Monday, April 21st. The shares were sold at an average price of $13.67, for a total transaction of $33,491.50. Following the completion of the sale, the insider now directly owns 263,152 shares in the company, valued at $3,597,287.84. This represents a 0.92 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 33,128 shares of company stock valued at $450,072. Corporate insiders own 30.10% of the company's stock.

Liquidia Stock Performance

Liquidia stock traded up $0.09 during midday trading on Friday, hitting $14.12. 584,669 shares of the company were exchanged, compared to its average volume of 961,553. Liquidia Co. has a fifty-two week low of $8.26 and a fifty-two week high of $16.81. The firm has a market capitalization of $1.20 billion, a PE ratio of -8.66 and a beta of 0.23. The business has a fifty day simple moving average of $14.40 and a two-hundred day simple moving average of $12.92.

Liquidia (NASDAQ:LQDA - Get Free Report) last posted its earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.08). Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. The firm had revenue of $2.92 million for the quarter, compared to analysts' expectations of $4.60 million. As a group, equities analysts expect that Liquidia Co. will post -1.51 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on LQDA. Scotiabank restated an "outperform" rating on shares of Liquidia in a research note on Thursday, March 20th. Needham & Company LLC restated a "buy" rating and issued a $25.00 price objective on shares of Liquidia in a research note on Thursday, April 10th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $29.00 target price on shares of Liquidia in a report on Thursday, March 20th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $26.63.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).